Researchers at Glasgow Caledonian University are looking for people with hepatitis C to take part in a short interview about their experiences of liver cancer screening. This will form part of a study called THRIVE-SVR.
What is the THRIVE-SVR study?
Liver cancer is a common cause of death in patients with hepatitis C. One important reason for this is that liver cancer is usually diagnosed at a late stage, when it is difficult to treat.
However, if liver cancer is diagnosed early (i.e. when the tumour is small) then the odds of survival are much better.
The THRIVE-SVR is a research study sponsored by the Medical Research Foundation. Its aim is to improve early detection of liver cancer in patients with cured hepatitis C. The way researchers are trying to do this is by developing “risk calculators” that will help doctors identify those patients who are most likely to develop liver cancer.
To help us understand the patient perspective, we would really love to talk to people who have first-hand experience of hepatitis C and liver cancer screening.
Who can get involved?
Researchers want to speak to patients who have (or have had in the past) a hepatitis C infection who have been diagnosed with liver cirrhosis. They are especially interested to hear from those who have a history of liver cancer or those who have been offered screening for liver cancer.
What will happen if I agree to take part?
Participants will be invited to take part in an informal Zoom call with two researchers. The call will last about 45 to 60 minutes. They will ask you questions about your experience and attitudes to liver cancer screening.
All participants will receive a £50 Amazon voucher as compensation for their time.
How to take part
If you would like to take part in the study, please email Hamish from Glasgow Caledonian University at Hamish.Innes@gcu.ac.uk.